Skip to content
Search

Latest Stories

Siddhant Chaturvedi on Bunty Aur Babli 2: I can’t wait to con everybody

Murtuza Iqbal

Siddhant Chaturvedi made his Bollywood debut with the film Gully Boy. His portrayal of MC Sher grabbed everyone’s attention and Siddhant also won many awards for his performance in the film.


The actor currently has many interesting projects lined-up and one of them is Bunty Aur Babli 2 which also stars Sharvari Wagh, Rani Mukerji, and Saif Ali Khan. Recently, while talking to Mumbai Mirror, Siddhant spoke about the film.

He stated, “It’s been around 15 years since the original and a lot has changed since. A family entertainer, it is about aspirations and corruption and appeals to all age groups. I can’t wait to con everybody.” Reportedly, The actor has five disguises in the film and a lot of prosthetics has been used for it.

Apart from Bunty Aur Babli 2, Siddhant has Shakun Batra’s next in his kitty which also stars Ananya Panday and Deepika Padukone. While talking about his co-star Deepika, the actor told the tabloid, “She submits herself completely and makes the character believable. I am living out my dream in every possible way.”

Siddhant will also be seen sharing screen space with Katrina Kaif and Ishaan Khatter in PhoneBhoot, and the actor says that it’s a hilarious script. He said, “It’s a hilarious script; we had a blast during the readings, there’s going to be some solid jugalbandi between the three of us. We want it to be the next pop culture.”

PhoneBhoot is a horror-comedy, but Siddhant is all set to star in an action film as well. The actor stated, “I’ve trained in mixed martial arts and taekwondo and it’s difficult holding back from sharing the training videos. The film was supposed to be announced before the pandemic; hopefully, you’ll hear of it soon.”

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less